Clazakizumab not checked

CSL Behring · CSL300 · BMS-945429

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
2 active
9 in total · 1 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“CSL300 is a humanized anti-interleukin 6 (anti-IL-6) monoclonal antibody (mAb).”In the company’s words, NCT07619820 on ClinicalTrials.gov
Tested for
End Stage Kidney Disease, End Stage Kidney Disease (ESKD)
Main trialPhase 2/3
“This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.”In the company’s words, NCT05485961 on ClinicalTrials.gov
Other names
CSL300 · BMS-945429 · ALD518

Other drugs for End Stage Kidney Disease

All 25 drugs for End Stage Kidney Disease

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting 22 May 2029 Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Phase 1Recruiting 30 Aug 2027 A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
Phase 3Terminated 8 Apr 2024 Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
Phase 2Completed Sep 2012 Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Phase 2Terminated Apr 2013 Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
Phase 2Completed Jun 2013 Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
Phase 2Completed Jun 2013 Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
Phase 2Terminated Dec 2013 Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Phase 1/2Terminated Mar 2013 Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Clazakizumab

Following is part of Solo: you see every change to Clazakizumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in